Quantcast

Latest Fentanyl Stories

2014-08-07 16:29:04

CUPERTINO, Calif., Aug. 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014. Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9 million and net loss of $5.1 million for the three months ended June 30, 2013. http://photos.prnewswire.com/prnvar/20020717/DRRXLOGO At June 30, 2014, we had cash and investments of $37.3 million, compared...

2014-08-04 16:26:29

NEWARK, Calif., Aug. 4, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of R. Scott Shively, as Chief Commercial Officer and Senior Vice President. Mr. Shively has extensive commercial leadership experience in sales and marketing of pain and neurology products, for both specialty as well as larger pharmaceutical companies. Mr. Shively served as Executive Vice President and Chief Commercial Officer of Zogenix from November 2012 through August...

2014-07-30 16:29:50

CUPERTINO, Calif., July 30, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, August 7, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time). http://photos.prnewswire.com/prnvar/20020717/DRRXLOGO A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2014-07-29 08:31:39

MELBOURNE, Australia, July 29, 2014 /PRNewswire/ -- -- Next phase of the TPM®/Oxymorphone clinical development program has commenced -- TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4 2014 -- TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in 1H 2015 Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today provided updates on its opioid transdermal patch programs after its...

2014-07-25 16:23:01

NEWARK, Calif., July 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2014 financial results after the market closes on Wednesday, August 6, 2014. The Company will host a conference call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on...

2014-07-23 08:32:46

WASHINGTON, July 23, 2014 /PRNewswire-USNewswire/ -- For critically ill patients arriving at the emergency department, the drug ketamine can safely provide analgesia, sedation and amnesia for rapid, life-saving intubation, despite decades-old studies that suggested it raised intracranial pressure. The results of a systematic review of 10 recent studies of what many emergency physicians regard as a "wonder drug" are published online today in Annals of Emergency Medicine ("The Effect...

2014-07-17 16:26:16

Opinion Expected "In Short Order" NEWARK, Calif., July 17, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise® (gabapentin) prior to the Court's issuance of an opinion in the matter. The order indicates the Court expects to issue an...

2014-07-16 08:27:57

NEWARK, Calif., July 16, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer and Senior Vice President. Dr. Rao has extensive experience and background in pain and central nervous system diseases. He was the Founder and Chief Executive Officer of Kyalin Biosciences, a privately held biotechnology company developing a potential breakthrough therapy for autism, from its formation in 2011 through to its...

2014-07-07 04:20:56

- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO(TM) for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISO(TM) is a drug-device...

2014-06-20 23:03:17

Las Vegas Rapid Detox Medical Clinic is pleased to announce that they reached the milestone of performing 500 successful rapid opiate detox procedures without any complications. Las Vegas, NV (PRWEB) June 20, 2014 Opiate detox can be an extremely painful thing to go thorugh. However, with Las Vegas Rapid Detox’s groundbreaking 8 hour rapid detox procedure, patients can detox from opiates in only eight hours without suffering any signs of withdrawal. Las Vegas Rapid Detox’s procedure...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related